Healthy Aging & Longevity

Tesamorelin / Ipamorelin

Pairs a clinically studied GHRH analog with a selective secretagogue for a broader growth hormone signal.

Baseline Labs Generally RequiredInjectableModerate evidenceCompounded
  • Physician reviewed
  • 503A pharmacy compounded
  • Patient-specific prescription

Formats & pricing

  • combination vial — reconstituted injectable$270
Start my CareSee how it works

Pricing reflects the compounded preparation and physician review. Final therapy and dosing are determined only after your intake is reviewed.

Overview

What is Tesamorelin / Ipamorelin?

This combination brings together tesamorelin's GHRH receptor activity with ipamorelin's ghrelin receptor selectivity, addressing two distinct arms of growth hormone regulation in one prescription.

Mechanism

How it works

The two peptides act at different receptors, which practitioners describe as additive: one amplifies the releasing signal, the other the secretory pulse, with minimal impact on cortisol or prolactin.

Wellness support

Potential wellness support areas

These areas are commonly discussed within wellness-focused protocols. They are educational statements, not medical claims or guarantees of outcome.

  • Explored for visceral fat and body composition
  • Discussed for recovery and sleep depth
  • Potential support for lean mass retention
  • Monitored with IGF-1 and metabolic labs

Administration

Format & dosing

Nightly subcutaneous injection. Cycle length and dosing are determined by your physician following intake and lab review.

Labs & monitoring

Labs, testing & monitoring

Your physician determines the final testing requirements for Tesamorelin / Ipamorelin after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.

Bloodwork status

Baseline Labs Generally Required

Commonly reviewed at baseline

  • IGF-1
  • Comprehensive metabolic panel (CMP)
  • Fasting glucose and A1c
  • Lipid panel
  • Thyroid panel (TSH, free T4)

Follow-up & monitoring

IGF-1 with fasting glucose and A1c at roughly 8 to 12 weeks, with dose adjustment based on the result.

Who may not be a candidate

  • Pregnancy or nursing
  • Active malignancy without oncology clearance
  • Known hypersensitivity to the preparation
  • Active pituitary disease
  • Uncontrolled diabetes

Medication interactions

Your physician reviews all prescriptions, supplements, and over-the-counter medications during intake before anything is prescribed.

Safety

Safety & considerations

Compounded, not FDA-approved. Contraindicated with active malignancy. Glucose and IGF-1 monitoring generally advised.

Regulatory status: Compounded. Evidence level: Moderate. Eligibility, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed physician after review of your history.

Physician reviewed

Every protocol is approved by a licensed physician.

503A compounded

Prepared by licensed US compounding pharmacies.

Patient-specific Rx

Prescriptions are issued in your name only.

No membership

No concierge fee and no subscription to browse or begin.

Ready when you are

Find out what your body is actually asking for.

Fill out a short intake form and our care team will build a plan grounded in your labs — not a guess from a supplement aisle.